Swot up on investing strategies by attending our September conference

Pharmaceutical companies are switching from mega mergers to more targeted, albeit high-priced, acquisitions.

Two thirds of the blue chip index have delivered share price gains this year

If the euro-sterling pair breaks through 0.7500 things could get interesting

Bullish signal for investors in bathroom fit-out specialist

Earnings-accretive deal is a good fit for aerospace and defence firm

It is ‘out with the old’ and ‘in with the new’ for investment fund

Series of approvals and clinical trial results expected in the next 12 months

Stocks trading below their historic average PE could represent compelling value opportunities. Tom Sieber and the Shares team identifY the names poised for a re-rating